ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and delivering dangerously high insulin doses, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026.